Methods of use of glutamine synthetase inhibitors
OwnerThang V. Nguyen, Raymond J. Deshaiesinventors
Life of this patent
Estimating the term…
Abstract
A method of treating neoplastic growth in a subject includes administering a glutamine synthetase (GS) inhibitor to the subject having neoplastic growth. A glutamine synthetase inhibitor may be administered in combination with thalidomide, lenalidomide and/or pomalidomide. Responsiveness to thalidomide, lenalidomide or pomalidomide therapy is determined by the expression levels of glutamine synthetase in neoplastic cells.
Claims17
A method of treating neoplastic growth, comprising:
- administering a composition comprising a glutamine synthetase (GS) inhibitor to a subject having the neoplastic growth.
A method of identifying a response to immunomodulatory drug (IMiD) and glutamine synthetase (GS) inhibitor therapy in a subject, comprising:
- measuring the level of glutamine synthetase (GS) protein in the subject before administering the IMiD and GS inhibitor therapy to the subject;
- administering IMiD and GS inhibitor therapy to the subject;
- and
- measuring the level of GS protein in the subject after administering the IMiD and GS inhibitor therapy, wherein a reduction in the level of GS protein in the subject after IMiD and GS inhibitor therapy is indicative of a response to the IMiD therapy.
A method of identifying the capability of a subject having neoplastic cell growth to respond to immunomodulatory drug therapy, the method comprising:
- determining the amount of glutamine synthetase expression in the neoplastic cell growth of the subject;
- determining the amount of glutamine synthetase expression in normal cells of the subject;
- wherein an increase in the expression of glutamine synthetase in the neoplastic cell growth compared to the expression of glutamine synthetase in normal cells of the subject indicates that the neoplastic cell growth of the subject is capable of responding to immunomodulatory drug therapy.
A composition for inhibiting neoplastic cell growth, comprising:
- thalidomide, lenalidomide and/or pomalidomide;
- and
- a glutamine synthetase inhibitor.
Dependencies are inferred from the claim text.